Literature DB >> 4029029

Comparative in vitro activity of temocillin.

M Gobernado, E Canton.   

Abstract

The antibacterial activity of temocillin, a novel beta-lactam antibiotic, was tested against 796 clinical isolates. We also conducted a comparative study against 8 other antibiotics. Temocillin exhibited good activity against Gram-negative organisms including Escherichia coli, and the genera Proteus, Enterobacter, Serratia, Klebsiella, Citrobacter, Providencia, Salmonella, Shigella and Haemophilus: 98% of the strains were inhibited by concentrations less than or equal to 16 mg/L. The results of this in vitro study and temocillin's favourable pharmacokinetic properties suggest that temocillin is a very promising penicillin for the treatment of hospital infections caused by Gram-negative organisms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029029     DOI: 10.2165/00003495-198500295-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  9 in total

1.  Monocyclic beta-lactam antibiotics produced by bacteria.

Authors:  R B Sykes; C M Cimarusti; D P Bonner; K Bush; D M Floyd; N H Georgopapadakou; W M Koster; W C Liu; W L Parker; P A Principe; M L Rathnum; W A Slusarchyk; W H Trejo; J S Wells
Journal:  Nature       Date:  1981-06-11       Impact factor: 49.962

2.  Comparative in vitro study of SQ26,776.

Authors:  V Fainstein; S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

3.  BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.

Authors:  B Slocombe; M J Basker; P H Bentley; J P Clayton; M Cole; K R Comber; R A Dixon; R A Edmondson; D Jackson; D J Merrikin; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

4.  In vitro activity of temocillin, a new beta-lactamase-stable penicillin active against enterobacteria.

Authors:  D Greenwood; A Cowlishaw; A Eley
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

5.  Comparative in vitro study of temocillin (BRL 17421), a new penicillin.

Authors:  R Bolivar; S S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  Antibacterial activity and beta-lactamase stability of temocillin.

Authors:  K Jules; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

7.  Comparative in-vitro activity of temocillin (BRL 17421), a new penicillin.

Authors:  A M Clarke; S J Zemcov
Journal:  J Antimicrob Chemother       Date:  1983-04       Impact factor: 5.790

8.  Comparative in vitro and in vivo activity of temocillin (BRL 17421) and ampicillin against Haemophilus influenzae type b.

Authors:  R Yogev; W Glogowski; E Connor
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

9.  In vitro activity of temocillin (BRL 17421), a novel beta-lactam antibiotic.

Authors:  H W Van Landuyt; M Pyckavet; A Lambert; J Boelaert
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

  9 in total
  3 in total

Review 1.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 2.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 3.  Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic.

Authors:  Tommaso Lupia; Ilaria De Benedetto; Giacomo Stroffolini; Stefano Di Bella; Simone Mornese Pinna; Verena Zerbato; Barbara Rizzello; Roberta Bosio; Nour Shbaklo; Silvia Corcione; Francesco Giuseppe De Rosa
Journal:  Antibiotics (Basel)       Date:  2022-04-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.